Newall Anthony T, Dehollain Juan Pablo
School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Sydney NSW 2052, Australia.
Vaccine. 2014 Mar 10;32(12):1323-5. doi: 10.1016/j.vaccine.2014.01.017. Epub 2014 Jan 28.
It is important to consider the value for money offered by existing elderly influenza vaccination programs, particularly as doubts persist about the magnitude of the effectiveness of such programs. An informative approach to explore the value of vaccination is to consider what vaccine efficacy would be required for a program to be considered cost-effective. To estimate the cost-effectiveness of the current elderly (65+ years) influenza vaccination program in Australia, we modelled how the hypothetical removal of vaccination would increase current disease burden estimates depending on alternative vaccine efficacy assumptions. The base-case results of the analysis found that the existing elderly vaccination program is likely to be cost-effective (under A$50,000 per quality-adjusted life year gained) if the vaccine efficacy is above ∼30%. This study offers reassurance that the influenza vaccination of elderly Australians is likely to offer value for money.
考虑现有老年人流感疫苗接种计划的性价比很重要，尤其是鉴于对此类计划有效性的程度仍存疑虑。一种探索疫苗接种价值的有益方法是考虑一个计划要被视为具有成本效益需要达到何种疫苗效力。为了估算澳大利亚当前针对65岁及以上老年人的流感疫苗接种计划的成本效益，我们构建了模型，以研究在不同的疫苗效力假设下，假设取消疫苗接种会如何增加当前疾病负担的估计值。分析的基础案例结果发现，如果疫苗效力高于约30%，现有的老年人疫苗接种计划可能具有成本效益（每获得一个质量调整生命年的成本低于50,000澳元）。这项研究让人放心，澳大利亚老年人接种流感疫苗可能物有所值。
